| JNTL Consumer Health II (Switzerland) GmbH - Nicorette Invisi 25 mg/ 16 h, transdermales Pflaster | | 58175 | | 03 | | Nicorette Invisi 25 mg/ 16 h | | transdermales Pflaster | | N07BA01 | | Nicotin | | 17.09.2009 | | |
| | Zusammensetzung | | nicotinum 39.37 mg, triglycerida media, copolymerum methacrylatis butylati basicum, poly(ethylenis terephthalas), 2-ethylhexylacrylate/butyracryltate/vinylacetate/acrylic acid Copolymer (75:15:5:5) in ethylacetate/heptane (85:15), kalii hydroxidum, carmellosum natricum conexum, aluminii acetylacetonas, Drucktinte (braun): ad praeparationem pro 22.50 cm², cum liberatione 25 mg/16h. | | Packungsbestandteile | | Transdermales Therapeutisches System | | | | | | Wirkstoffe | Stärke |
|---|
| Nicotine | 39.37 mg |
| | | | Hilfsstoffe |
|---|
| 2-ethylhexylacrylate/butyracryltate/vinylacetate/acrylic acid Copolymer (75:15:5:5) in Ethylacetate/heptane (85:15) | | Aluminii Acetylacetonas | | Carmellosum Natricum Conexum | | Copolymerum Methacrylatis Butylati Basicum | | Kalii Hydroxidum | | Triglycerida Media |
|
| | Packungsnummer | Packungsgrösse | EFP | PP | Kat. | SL | In Refdata nicht gelistet |
|---|
| 007 | 14 Pflaster | | | D | | Nein |
|
|
